Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phase III Anxiety Drug Trial Misses Endpoints

gurufocus.com · 2026-10-15

On October 15, 2026, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) saw its shares decline 2% in premarket trading following the announcement that its Phase III trial

TickrTrends take: Vanda Pharmaceuticals faced negative momentum in premarket trading following its Phase III trial setback for an anxiety treatment, which represents a meaningful near-term headwind for a clinical-stage program. Despite this clinical disappointment, TickrTrends currently assesses VNDA as undervalued, suggesting the market reaction may have overcorrected relative to the company's broader asset portfolio and pipeline prospects. Investors focused on valuation metrics should monitor whether the company's existing marketed products and remaining pipeline candidates can offset the lost revenue potential from this failed program and support near-term financial performance.

Read the full story at gurufocus.com →